• Dianthus Therapeutics launched the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis, with top-line results expected in 2H'28.
• The global, placebo-controlled study will enroll about 195 AChR-positive patients, testing subcutaneous dosing every two or four weeks.
• Phase 2 MaGic results were presented in September 2025, showing rapid, sustained symptom improvement versus placebo.
• The Phase 2 program reported no drug-related serious adverse events or discontinuations, supporting the move into late-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290700PRIMZONEFULLFEED9753707) on June 29, 2026, and is solely responsible for the information contained therein.